Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cphi .32 New Product Launch Watch 1 mill float
***** ONLY 1 month left of first half 2024 news could come any day
Coming 1st Half 2024 ..
—> Dry Eye Disease (DED) therapeutic device
QUOTE from -> 2023 News
“”We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."”
after split 1-for 5 (3/6/24)
1 Million float
10 Mill o/s
Insiders own 86% per finviz*
Chart -> https://schrts.co/EjjTrTmK
Finviz -> https://finviz.com/quote.ashx?t=CPHI&p=d
News —> 11/29/23
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.
According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.
This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html
SOURCE China Pharma Holdings, Inc.
Copyright 2023 PR Newswire
JAGX.....TUP.....SYRA.....CKPT.....https://stockcharts.com/h-sc/ui?s=AGBA&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=TUP&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=SYRA&p=D&yr=0&mn=3&dy=0&id=p11960084343
https://stockcharts.com/h-sc/ui?s=CKPT&p=D&yr=0&mn=3&dy=0&id=p11960084343
ADAP......AGBA.......CHPT.......BLNK.......https://stockcharts.com/h-sc/ui?s=ADAP&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=AGBA&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=CHPT&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=BLNK&p=W&yr=1&mn=3&dy=0&id=p96837884856
MAPS.....ATOS.....NKTR......VERU......https://stockcharts.com/h-sc/ui?s=MAPS&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=ATOS&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=NKTR&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=VERU&p=W&yr=1&mn=3&dy=0&id=p96837884856
TLRY........SNDL......RZLT......FNGR......https://stockcharts.com/h-sc/ui?s=FNGR&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=RZLT&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=SNDL&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=TLRY&p=W&yr=1&mn=3&dy=0&id=p96837884856
$WHALE ---> What's the next strategy?
BRIUNS going to beat them Maple Leafs in da "GARDEN" SETUP total brawl for the win....?
"I" hope you are trading that SPX well brother!
$ I am just picking, "I" had 2 set you apart. :) gltu brother. say hi to your boss for me.
"FULL THROTTLE & CHAMPAGNE BOTTLES"
MARK nice, missed it. (:.
oh but "I" will be watching it Monday.
Thanks, brother ORION.
$SGE 2.00 guess it did not want to wait till next week, 1.9m float
* * > $ALLR < * *
5,000 $1.08
5,000 $1.01
swinging
$1.045 avg
https://elite.finviz.com/published_idea.ashx?t=ALLR&f=050324&i=ALLRi30171225612i
"FULL THROTTLE & CHAMPAGNE BOTTLES"
Theres a pending product launch this quarter > watch for news
Wed, Nov 29, 2023
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."
They constantly dilute, might get a pop every now and then but not a swing.
$SGE 1.17 Acquisition news, one to watch next week
Cphi .31 post r/s 86% insider ownership 1 mill float
https://finviz.com/quote.ashx?t=CPHI&p=d
Watching for the news
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
PR Newswire
Wed, Nov 29, 20233 min read
In This Article:
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.
According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.
This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
BTC new hod... RIOT should creep back uP here…
CSLR $1 going to need battering ram...lol
Cphi $.32 -1 Mill float news watch medical device launch first half of 2024
News from —> 11/29/23
QUOTE
“”We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."”
after split 1-for 5 (3/6/24)
1 Million float
10 Mill o/s
Insiders own 86% per finviz*
Chart -> https://schrts.co/EjjTrTmK
Finviz -> https://finviz.com/quote.ashx?t=CPHI&p=d
News —> 11/29/23
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device
Source: PR Newswire (US)
HAIKOU, China, Nov. 29, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma", or the "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced that its Dry Eye Disease (DED) therapeutic device has passed third-party testing and is preparing to apply for market launch to the National Medical Products Administration (NMPA) of China.
According to a disclosure by the Shanghai Public Health Clinical Center on June 6, 2023, an epidemiological survey of DED showed that approximately 344 million patients are suffering from DED worldwide, accounting for 30% of the total number of ophthalmic outpatient visits, with an annual increase of 10%. There are about 80 million DED patients in China, ranking second in ophthalmic diseases.
This device has a utility model patent;
Epidemiological research shows that the incidence rate of DED for all the people in China is about 25% to 30%, and about 75% for people over 65-year-old;
In the field of DED and visual fatigue, this product is expected to fill in the market gap of medical therapeutic apparatus; and
The Company has established sales channels in more than 30 provincial and municipal hospitals, as well as OTC markets in China for more than 20 years. This sales network may strongly support the launch and promotion of this device.
Ms. Li Zhilin, CEO of China Pharma said: " After passing third-party testing, this product has obtained qualifications to apply for market approval from NMPA. We are actively working to try to launch this product in the first half of next year. We are confident that with the patented technological advantages and our sales channels, the launch of this product will bring excellent treatment experience to every DED patient, which will create value for our shareholders."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit www.chinapharmaholdings.com. The Company routinely posts important information on its website.
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation.
Cision View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-the-completion-of--third-party-testing-of-dry-eye-disease-therapeutic-device-302000153.html
SOURCE China Pharma Holdings, Inc.
Copyright 2023 PR Newswire
TUP.............EZGO...............................https://stockcharts.com/h-sc/ui?s=EZGO&p=W&yr=1&mn=3&dy=0&id=p96837884856
https://stockcharts.com/h-sc/ui?s=TUP&p=W&yr=1&mn=3&dy=0&id=p96837884856
Smart investors loading up on $SINT stock
You do the same…🥳
I want people to not only make money, but to preserve it...so when I say it's time to be cash (which I was correct about last time) maybe listen..JMHO
I was flush with cash when it was time to load all these bottomed out charts & now riding em up...
When I say it's time to buy calls & be in the market, same deal...GET IN! ;)
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174314009
I put my market direction skills up against anyone in the world!
Yeah - I sold yesterday at open for a small profit; jumped into PARA late afternoon - sold PARA this morning at $14.30 and bebopped back over to VHAI and ended up with more shares than what I sold yesterday, so it's been a good Friday.
VHAI should do well, once they decide to let 'er go. Perhaps next week.
yes, it's my #1 holding, my dog with fleas LMAO...it's ok, I officially doubled plus my account today from last week...it's absorbed, so not worried about it hehehe
You still in VHAI?
I think we have until end of month to be full bull...I will alert when it's time to get to cash again...good luck & congrats if you listened & bought calls all week!! ;)
60% in stocks, cashed in calls every day for HUGE money...what a WEEK!!!!
Have a good one...
No worries it’ll double from here CSLR
CSLR .89 nhod
RIOT itching to bust $10.50 here…
$SINT Power Hour Here next week .10 coming get your cheap shares today
EFTR on the runway too ;)
BENF it’s got eleven bucks in it still
CSLR, $1+ is party on Garth!
RNAZ .97 …+ 37% a 1.09 break 2.16 then 5.42 slow but steady many holding here a few months
RNAZ .92 + 30% similar to EFTR 2.25 +’ 4% beat downs coming off bottoms
Followers
|
2516
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
642227
|
Created
|
06/03/08
|
Type
|
Free
|
Moderator AugustaFriends | |||
Assistants jobynimble JDUB Mark |
Sign up for Email Updates: http://investorshub.advfn.com/boards/chairmail_sub.asp?board_id=12753
Chart Lessons by IAMGEND - A must learn for all traders
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76625096
Chart tools:
(1) I use http://www.stockcharts.com for charting
(2) For more info on chart formations, see http://www.chartpatterns.com
(3) Chart indicator definitions http://stockcharts.com/education/IndicatorAnalysis/
(4) Explore Level II here-http://www.hotstockmarket.com/forums/showthread.php?t=14938
(5) For a COMPLETE list of indicator meanings http://www.investopedia.com/categories/technicalanalysis.asp
(6) Top insider trades website: http://www.secform4.com/top-lists.htm
BOARD FOR IHUBS HOTTEST CHART PLAYS
http://investorshub.advfn.com/boards/board.aspx?board_id=18372
WHO'S HOT: http://investorshub.advfn.com/boards/hot_people.asp
CHART YOUR STOCKS HERE: http://stockcharts.com/index.html http://www.profitspi.com/
INSTANT TECHNICAL ANALYSIS: http://www.barchart.com/
NEWS FILTER: http://www.marketwatch.com/
GOOD READ: http://www.bloggingstocks.com/
ALL ABOUT TRADERS: http://www.tradersmagazine.com/
TRACK WHAT THE FUNDS ARE DOING - MY FAVORITE SITE!: http://www.mffais.com
COMMENTARY ON EVERYTHING STOCKS: http://www.istockanalyst.com/
BEST ONLINE BROKERAGE:http://www.nobletrading.com/index.php (ask for Efrain)
MARKET MAKERS: http://www.otcbb.com/dynamic/tradingdata/download/mmids.txt
SHORT DATA: http://shortsqueeze.com/
SEC FILINGS: http://www.sec.gov/edgar/searchedgar/companysearch.html
WALL STREET TABLOID: http://dealbreaker.com/
Posts Today
|
2
|
Posts (Total)
|
642227
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |